BRPI0604461A - composição farmaceutica estavel de carisoprodol e meloxicam - Google Patents

composição farmaceutica estavel de carisoprodol e meloxicam

Info

Publication number
BRPI0604461A
BRPI0604461A BRPI0604461-1A BRPI0604461A BRPI0604461A BR PI0604461 A BRPI0604461 A BR PI0604461A BR PI0604461 A BRPI0604461 A BR PI0604461A BR PI0604461 A BRPI0604461 A BR PI0604461A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
carisoprodol
meloxicam
stable pharmaceutical
inflammatory
Prior art date
Application number
BRPI0604461-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Antonio Santiago Regalado
Sixto Serafin Espinoza Leon
Original Assignee
Silanes Sa De Cv Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silanes Sa De Cv Lab filed Critical Silanes Sa De Cv Lab
Publication of BRPI0604461A publication Critical patent/BRPI0604461A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0604461-1A 2006-04-03 2006-10-09 composição farmaceutica estavel de carisoprodol e meloxicam BRPI0604461A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06003717A MXPA06003717A (es) 2006-04-03 2006-04-03 Composiciones oftalmicas de proteinas inhibidoras de citocinas implicadas en procesos inflamatorios o inmunologicos.

Publications (1)

Publication Number Publication Date
BRPI0604461A true BRPI0604461A (pt) 2007-04-17

Family

ID=37450733

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0604461-1A BRPI0604461A (pt) 2006-04-03 2006-10-09 composição farmaceutica estavel de carisoprodol e meloxicam

Country Status (3)

Country Link
BR (1) BRPI0604461A (fr)
MX (1) MXPA06003717A (fr)
WO (1) WO2007114680A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
MX367136B (es) 2012-10-18 2019-08-06 Inosan Biopharma S A Star Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye

Also Published As

Publication number Publication date
WO2007114680A1 (fr) 2007-10-11
MXPA06003717A (es) 2006-09-29

Similar Documents

Publication Publication Date Title
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BRPI0515815B8 (pt) forma medicamentosa de multipartículas contendo substâncias ativas de ácido nucléico formuladas mucoadesivas, bem como seu processo de preparação
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
EA202091999A3 (ru) Применение ингибиторов dpp iv
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
RS51688B (en) METHOTREXATE CONCENTRATED SOLUTIONS
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
SV2010003497A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
BR112014012628A2 (pt) di-hidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
AR069211A1 (es) Derivados de acidos de 1,2,4-oxadiazol ciclobutanoamino carboxilicos, una composicion farmaceutica, proceso de preparacion del compuesto y su uso para preparar medicamentos
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
ECSP099348A (es) Composición farmacéutica de liberación modificada de un músculo relajante y un aine
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
AR048958A1 (es) Medicamento en forma de pelicula para administracion por via oral, que contiene estriol
BRPI0604461A (pt) composição farmaceutica estavel de carisoprodol e meloxicam
UY30550A1 (es) Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: PAGAR RESTAURACAO.

B06G Technical and formal requirements: other requirements

Free format text: CONFORME O ART. 220 DA LPI, PARA QUE SEJA ACEITA A PETICAO NO 018150001487 DE 04/02/2015, O INTERESSADO DEVERA APRESENTAR PROCURACAO ATRIBUINDO PODERES AO SIGNATARIO DA MESMA NA FORMA DO ART. 216, INCISO II DA LPI.

B08G Application fees: restoration
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled
B07A Technical examination (opinion): publication of technical examination (opinion)
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.